BG102214A - Derivatives of azetidinons for the treatment of atherosclerosis - Google Patents

Derivatives of azetidinons for the treatment of atherosclerosis

Info

Publication number
BG102214A
BG102214A BG102214A BG10221498A BG102214A BG 102214 A BG102214 A BG 102214A BG 102214 A BG102214 A BG 102214A BG 10221498 A BG10221498 A BG 10221498A BG 102214 A BG102214 A BG 102214A
Authority
BG
Bulgaria
Prior art keywords
alkyl
optionally
aryl
value
whichcan
Prior art date
Application number
BG102214A
Other languages
Bulgarian (bg)
English (en)
Inventor
Dashyant Dhanak
Deirdre HICKEY
Robert IFE
Colin LEACH
David TEW
Original Assignee
Smithkline Beecham P.L.C.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB9513442.5A external-priority patent/GB9513442D0/en
Priority claimed from GBGB9515056.1A external-priority patent/GB9515056D0/en
Priority claimed from GBGB9515206.2A external-priority patent/GB9515206D0/en
Priority claimed from GBGB9516985.0A external-priority patent/GB9516985D0/en
Priority claimed from GBGB9525132.8A external-priority patent/GB9525132D0/en
Priority claimed from GBGB9608651.7A external-priority patent/GB9608651D0/en
Priority claimed from GBGB9608650.9A external-priority patent/GB9608650D0/en
Application filed by Smithkline Beecham P.L.C. filed Critical Smithkline Beecham P.L.C.
Publication of BG102214A publication Critical patent/BG102214A/xx

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D205/00Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom
    • C07D205/02Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings
    • C07D205/06Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
    • C07D205/08Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with one oxygen atom directly attached in position 2, e.g. beta-lactams
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D205/00Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom
    • C07D205/02Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings
    • C07D205/06Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
    • C07D205/08Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with one oxygen atom directly attached in position 2, e.g. beta-lactams
    • C07D205/085Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with one oxygen atom directly attached in position 2, e.g. beta-lactams with a nitrogen atom directly attached in position 3
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D205/00Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom
    • C07D205/02Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings
    • C07D205/06Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
    • C07D205/08Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with one oxygen atom directly attached in position 2, e.g. beta-lactams
    • C07D205/09Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with one oxygen atom directly attached in position 2, e.g. beta-lactams with a sulfur atom directly attached in position 4
    • C07D205/095Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with one oxygen atom directly attached in position 2, e.g. beta-lactams with a sulfur atom directly attached in position 4 and with a nitrogen atom directly attached in position 3
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D405/00Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D409/00Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D417/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
BG102214A 1995-07-01 1998-01-28 Derivatives of azetidinons for the treatment of atherosclerosis BG102214A (en)

Applications Claiming Priority (8)

Application Number Priority Date Filing Date Title
GBGB9513442.5A GB9513442D0 (en) 1995-07-01 1995-07-01 Novel compounds
GBGB9515056.1A GB9515056D0 (en) 1995-07-22 1995-07-22 Novel compounds
GBGB9515206.2A GB9515206D0 (en) 1995-07-25 1995-07-25 Novel compounds
GBGB9516985.0A GB9516985D0 (en) 1995-08-18 1995-08-18 Novel compounds
GBGB9525132.8A GB9525132D0 (en) 1995-12-08 1995-12-08 Novel compounds
GBGB9608651.7A GB9608651D0 (en) 1996-04-26 1996-04-26 Novel compounds
GBGB9608650.9A GB9608650D0 (en) 1996-04-26 1996-04-26 Novel compounds
PCT/EP1996/002765 WO1997002242A1 (fr) 1995-07-01 1996-06-20 Derives de l'azetidinone pour le traitement de l'atherosclerose

Publications (1)

Publication Number Publication Date
BG102214A true BG102214A (en) 1998-08-31

Family

ID=27562921

Family Applications (1)

Application Number Title Priority Date Filing Date
BG102214A BG102214A (en) 1995-07-01 1998-01-28 Derivatives of azetidinons for the treatment of atherosclerosis

Country Status (23)

Country Link
EP (1) EP0840725A1 (fr)
JP (1) JP2002515852A (fr)
KR (1) KR19990028630A (fr)
CN (1) CN1197452A (fr)
AP (1) AP728A (fr)
AU (1) AU708032B2 (fr)
BG (1) BG102214A (fr)
BR (1) BR9609445A (fr)
CA (1) CA2225627A1 (fr)
CZ (1) CZ422197A3 (fr)
EA (1) EA199800109A1 (fr)
HU (1) HUP9901153A3 (fr)
IL (1) IL122650A0 (fr)
MA (1) MA23922A1 (fr)
MX (1) MX9800186A (fr)
NO (1) NO976158L (fr)
NZ (1) NZ311684A (fr)
OA (1) OA10648A (fr)
PE (1) PE8998A1 (fr)
PL (1) PL324240A1 (fr)
SK (1) SK178497A3 (fr)
TR (1) TR199701762T1 (fr)
WO (1) WO1997002242A1 (fr)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0869943A1 (fr) * 1995-12-08 1998-10-14 Smithkline Beecham Plc Derives de beta-lactame monocycliques utilises dans le traitement de l'atherosclerose
HUP9901359A3 (en) * 1996-04-26 2000-03-28 Smithkline Beecham Plc Azetidinone derivatives for the treatment of atherosclerosis, process for their producing and pharmaceutical compositions containing them
GB9608649D0 (en) * 1996-04-26 1996-07-03 Smithkline Beecham Plc Novel compounds
CZ304450B6 (cs) 2000-02-16 2014-05-14 Smithkline Beecham P. L. C. Pyrimidinový derivát
GB0024808D0 (en) 2000-10-10 2000-11-22 Smithkline Beecham Plc Novel compounds
BRPI0721697A2 (pt) 2007-05-11 2014-08-05 Univ Jefferson " métodos para tratar e/ou prevenir uma doença ou distúrbio neurodegenerativo em um indivíduo, para tratar e/ou prevenir um indivíduo com ou em risco de demência vascular, para tratar e/ou prevenir uma doença ou distúrbio associado com uma barreira hematoencefálica anormal em um indivíduo, para diminuir o acúmulo beta amilóide no cérebro de um indivíduo, para tratar e/ou prevenir mal de alzheimer em um indivíduo e para prevenir ou reduzir o risco de desenvolver mal de alzhheimer, e, uso de um agente que inibe a expressão e/ou atividade da proteína lp-pla2."
AU2008251467B2 (en) 2007-05-11 2014-07-31 The Trustees Of The University Of Pennsylvania Methods of treatment of skin ulcers
US8962633B2 (en) 2007-05-11 2015-02-24 Thomas Jefferson University Methods of treatment and prevention of metabolic bone diseases and disorders
WO2012076435A1 (fr) 2010-12-06 2012-06-14 Glaxo Group Limited Composés de pyrimidinone utiles dans le traitement de maladies ou d'états pathologiques induits par la lp-pla2
WO2012080497A2 (fr) 2010-12-17 2012-06-21 Glaxo Group Limited Procédés de traitement et de prévention de maladies oculaires
WO2013000267A1 (fr) 2011-06-27 2013-01-03 中国科学院上海药物研究所 Composé hétérocyclique azole, procédé de préparation, composition pharmaceutique et utilisation
TW201321382A (zh) 2011-07-27 2013-06-01 Glaxo Group Ltd 化合物
BR112014001665A2 (pt) 2011-07-27 2017-02-14 Glaxo Group Ltd compostos de 2,3-di-hidroimidazo[1,2-c]pirimidin-5(1h)-ona utilizados como inibidores de lp-plaz
BR112015017397A2 (pt) 2013-01-25 2017-07-11 Glaxosmithkline Ip Dev Ltd compostos pirimidona bicíclica como inibidores de lp-pla2
KR20150111356A (ko) 2013-01-25 2015-10-05 글락소스미스클라인 인털렉츄얼 프로퍼티 디벨로프먼트 리미티드 화합물
UY35276A (es) 2013-01-25 2014-08-29 Glaxosmithkline Ip Dev Ltd Nuevos compuestos que inhiben la actividad de Lp-PLA2
WO2016012917A1 (fr) 2014-07-22 2016-01-28 Glaxosmithkline Intellectual Property Development Limited Dérivés 1,2,3,5-tétrahydro-imidazo [1,2-c]pyrimidine utiles pour le traitement de maladies et de troubles médiés par la lp-pla2
WO2016012916A1 (fr) 2014-07-22 2016-01-28 Glaxosmithkline Intellectual Property Development Limited Dérivés 1,2,3,5-tétrahydro-imidazo [1,2-c]pyrimidine utiles pour le traitement de maladies et de troubles médiés par la lp-pla2
MX2022005615A (es) 2019-11-09 2022-07-27 Shanghai Simr Biotechnology Co Ltd Derivado triciclico de dihidroimidazopirimidona, metodo de preparacion del mismo, composicion farmaceutica y uso del mismo.
CN115304620A (zh) 2021-05-07 2022-11-08 上海赛默罗生物科技有限公司 嘧啶酮衍生物、其制备方法、药物组合物和用途

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4680391A (en) * 1983-12-01 1987-07-14 Merck & Co., Inc. Substituted azetidinones as anti-inflammatory and antidegenerative agents
IL89835A0 (en) * 1988-04-11 1989-12-15 Merck & Co Inc Substituted azetidinones,their preparation and pharmaceutical compositions containing them
IL99658A0 (en) * 1990-10-15 1992-08-18 Merck & Co Inc Substituted azetidinones and pharmaceutical compositions containing them
GB9421816D0 (en) * 1994-10-29 1994-12-14 Smithkline Beecham Plc Novel compounds
JPH11500415A (ja) * 1994-12-22 1999-01-12 スミスクライン・ビーチャム・パブリック・リミテッド・カンパニー アテローム性動脈硬化症治療用置換アゼチジン−2−オン

Also Published As

Publication number Publication date
PE8998A1 (es) 1998-03-20
CA2225627A1 (fr) 1997-01-23
MX9800186A (es) 1998-07-31
KR19990028630A (ko) 1999-04-15
JP2002515852A (ja) 2002-05-28
HUP9901153A3 (en) 1999-11-29
AU6305096A (en) 1997-02-05
AU708032B2 (en) 1999-07-29
NO976158L (no) 1998-02-25
OA10648A (en) 2002-09-25
MA23922A1 (fr) 1996-12-31
IL122650A0 (en) 1998-08-16
HUP9901153A2 (hu) 1999-08-30
SK178497A3 (en) 1998-07-08
BR9609445A (pt) 1999-04-06
TR199701762T1 (xx) 1998-05-21
AP9701161A0 (en) 1998-01-31
EP0840725A1 (fr) 1998-05-13
NZ311684A (en) 2000-04-28
WO1997002242A1 (fr) 1997-01-23
EA199800109A1 (ru) 1998-10-29
NO976158D0 (no) 1997-12-30
CN1197452A (zh) 1998-10-28
AP728A (en) 1999-01-29
PL324240A1 (en) 1998-05-11
CZ422197A3 (cs) 1998-06-17

Similar Documents

Publication Publication Date Title
BG102214A (en) Derivatives of azetidinons for the treatment of atherosclerosis
EP0760657A4 (fr) Nouveaux inducteurs puissants de la differenciation terminale et leurs procedes d'utilisation
KR950700894A (ko) 탁솔 유도체(Taxol derivatives)
TR199800011T1 (xx) Benzo$g] kuinolin t�revleri
MX9705590A (es) Compuestos heterociclicos sustituidos, procedimiento para su preparacion y composiciones que los contienen.
ATE27810T1 (de) 2-(3-iod-2-propinyloxy)-ethanol-carbamate, ihre herstellung und ihre verwendung als antimikrobielle substanzen.
ES2134815T3 (es) Nuevos potentes inductores de la diferenciacion terminal y metodos de uso de los mismos.
TR199701173T1 (xx) Yeni arilglisinamid t�revleri, bunlar�n �retilmesine mahsus usul.
TR199802160T2 (xx) Ateroskleroz tedavisi i�in azetidinon t�revleri.
BR1100061A (pt) Composto, processo para a preparação do mesmo, composição e uso dos mesmos
MX9706394A (es) Compuestos de 1-aril-2-acilamino-etano y su uso como antagonistas de neuroquinina, especialmente neuroquinina-1.
HUT75532A (en) Diacyl-substituted guanidine derivatives, process for producing them and pharmaceutical compositions containing them
PL315052A1 (en) Condensed dihydropyridines, method of obtaining them, their application in producing pharmaceutic preparations and pharmaceutic preparations containing such compounds
TW238304B (en) A process for the preparation of 1-substituted-5(4H)-tetrazolinones
GR3023757T3 (en) Cyclic benzylamino, benzylamido and benzylimido derivatives as antipsychotic agents.
DE69526097D1 (de) Bicyclische carboxamide als 5-ht1a rezeptoren liganden
PE68299A1 (es) 1,2,3,4-tetrahidroisoquinolinas terapeuticas
GB9612600D0 (en) Chemical compounds
RU98112496A (ru) Производные 5-нафталин-1-ил-1,3-диоксана, их получение и терапевтическое применение
DE69810294T2 (de) Calixaren-röhren als kationenrezeptoren
MX9804482A (es) Quinolinas y quinazolinas utiles en terapias.
ES2056025A1 (es) Nuevos derivados de indol.
EP0165032A3 (fr) Dihydropyridines anti-ischémiques et antihypertensives